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BACKGROUND: Vulval intraepithelial neoplasia (VIN) is a premalignant condition, which is frequently associated with type HPV16
infection, and multifocal disease has high rates of surgical treatment failure.
METHODS: We report a phase II clinical trial of the topical immunomodulator, imiquimod, for 8 weeks, followed by 3 doses (weeks 10,
14 and 18) of therapeutic human papillomavirus (HPV) vaccination (TA-CIN, fusion protein HPV16 E6E7L2) in 19 women with VIN
grades 2 and 3. Histology and HPV testing of biopsies were performed at weeks 0, 10, 20 and 52. Intralesional infiltration of T-cell
subsets and lymphocyte proliferation for HPV systemic immune responses were also assessed.
RESULTS: Lesion response (complete regression of VIN on histology) was observed in 32% (6 out of 19) of women at week 10,
increasing to 58% (11 out of 19) at week 20 and 63% (12 out of 19) at week 52. At this time, 36% (5 out of 14) of lesions showed
HPV16 clearance and 79% (15 out of 19) of women were symptom free. At week 20, after treatment with imiquimod and
vaccination, there was significantly increased local infiltration of CD8 and CD4 T cells in lesion responders; in contrast, non-
responders (persistent VIN by histology) showed an increased density of T regulatory cells. After vaccination, only lesion responders
had significantly increased lympho-proliferation to the HPV vaccine antigens.
CONCLUSION: The therapeutic effect of treatment depends on the differential immune response of responders and non-responders
with affect locally and systemically.
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Vulval intraepithelial neoplasia (VIN) is increasing in incidence,
and more so in younger women. A 4400% increase in the
incidence of VIN has been reported between 1973 and 2000,
whereas the corresponding increase in incidence of vulval cancer
has only been 20% (Akerman et al, 2007). This probably reflects an
increasing incidence of human papillomavirus (HPV) high-risk
type genital tract infections, as the most common type of VIN
(usual or undifferentiated) shows over 85% HPV positivity, with
type 16 DNA being detected in 75% of high-grade VIN (De Vuyst
et al, 2009). HPV infection of the lower genital tract and its
outcome are influenced by host immune response, virulence of the
HPV, smoking and immunosuppression (Duong and Flowers,
2007; Sherman et al, 2008). Successful adaptive immune responses
that lead to clearance of genital HPV infection are believed to be
mediated by local T cell-mediated immunity (Farhat et al, 2009).
The virus life cycle and several immune evasion mechanisms limit
virus-specific immunity, facilitating persistent infection and the
increased risk of carcinogenesis (Stern, 2005). Indeed, it has been
shown that patients with persistent HPV infection have depleted
T-cell responses against the viral early gene products E2 and E6
measured systemically (de Jong et al,2 0 0 4 ;F a r h a tet al,2 0 0 9 ) .I n
addition, T regulatory cells are negative regulators of otherwise
useful anti-tumour T-cell immunity and locally increased levels have
been implicated in the persistence of both cervical and vulval HPV-
associated lesions (van der Burg et al, 2007; Winters et al,2 0 0 8 ) .
VIN, which is often multifocal and extensive, has been
traditionally treated by surgical excision or laser ablation, but
such therapies are associated with high rates of recurrence (Jones
et al, 2005). Unfortunately, for patients with chronic VIN, younger
age and extent of surgery correlate directly with psychological
morbidity and poorer sexual function (Thuesen et al, 1992; Likes
et al, 2007; Shylasree et al, 2008). The natural history of VIN can be
viewed as a struggle between HPV-driven premalignant intra-
epithelial neoplasia and immune control mechanisms. With time,
the selection of cells with a malignant phenotype and ability to
escape the immune control can result in vulval cancer. Non-
surgical management of VIN with anti-viral and anti-neoplastic
agents has had limited success (Vilmer et al, 1998; Tristram and
Fiander, 2005), but a rational therapeutic strategy for chronic VIN
could aim to alter the local immune response in favour of
clearance of persistently HPV-infected cells.
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sSeveral different clinical studies influencing local and/or
systemic immunity to HPV using imiquimod, photodynamic
therapy (PDT) and therapeutic HPV vaccination in the manage-
ment of VIN have been reported. Imiquimod, an immune response
modifier that exerts an effect through a Toll-like receptor (TLR),
(Schon and Schon, 2007) can stimulate not only local innate
immunity (non-specific) with potent anti-tumoural effects but also
drive an adaptive immune response (e.g., specific T-cell effectors)
in secondary lymphoid tissues by activating tissue antigen-
presenting cells. In a recent randomised controlled trial, treatment
of VIN with imiquimod twice weekly for 16 weeks resulted in a
X25% lesion size reduction at 20 weeks in 81% of patients
compared with none in the placebo group (van Seters et al, 2008).
PDT uses a combination of light and photosensitiser drug to
damage tumour tissue by modifying cellular functions, inducing
cell death by necrosis or apoptosis, and encourages inflammation
and anti-tumour immunity (Castano et al, 2006). Studies using
PDT have shown good symptom and clinical response in patients
with VIN (Martin-Hirsch et al, 1998; Fehr et al, 2001; Olejek et al,
2008). A recent trial of combined treatment with imiquimod
followed by PDT (Winters et al, 2008) showed an overall lesion
response rate of 55%, with 30% showing complete lesion
resolution at 52 weeks. In this study, non-responders showed a
significantly higher level of T regulatory cells in the lesions after
imiquimod treatment (Winters et al, 2008). Such response rates
are clinically relevant, and the treatment regimen was feasible for
the majority. Non-responders to imiquimod seem to be relatively
refractory, and this may derive from their unfavourable local
immune environment, in particular, increased proportions of
T regulatory cells, limiting the action and development of any HPV
T-cell immunity. Therapeutic HPV vaccines are designed to
generate cell-mediated immunity against HPV-infected cells that
express the early viral proteins E6 and E7, which exert an effect as
oncogenes and also tumour-specific antigens. Clinical trials using
either PDT or therapeutic HPV vaccination have shown an
association between clinical responses and tumour-infiltrating
lymphocytes (TILs) (Abdel-Hady et al, 2001; Davidson et al,
2003a).
Optimal therapeutic immunity results from the interaction of
nonspecific innate immunity and antigen-specific adaptive im-
munity. Stimulation of the local innate immunity can have a direct
controlling effect on virally infected cells as well as attracting local
infiltration of TILs (Dermime et al, 2002). The challenge is to get
the most useful balance of helper (CD4) and cytotoxic (CD8) T-cell
infiltration, which are associated with positive prognosis, and
minimise the T regulatory cell infiltration, which is known to be
associated with poor outcome, as shown in several studies of
gynaecological cancer (Kondratiev et al, 2004; Sato et al, 2005;
Wolf et al, 2005; van der Burg et al, 2007). The rationale of this
study was that an initial local imiquimod treatment, in addition to
having a direct effect on VIN, can also provide an immunological
platform for the therapeutic HPV vaccination to achieve an
enhanced and durable response.
In this phase II trial, we used a combination of imiquimod and
vaccination with TA-CIN, which is a subunit vaccine comprising a
HPV16 E6E7L2 fusion protein, proven safe and immunogenic in
previous phase I and II trials (de Jong et al, 2002; Davidson et al,
2004; Smyth et al, 2004).
PATIENTS AND METHODS
Women aged 18–70 years with biopsy-proven VIN grades 2 and 3
were recruited between March 2006 and May 2007. Exclusion
criteria were pregnancy, invasive disease, immunosuppression,
history of severe allergy and previous HPV vaccination. Imiqui-
mod 5% cream was self-administered for 8 weeks, escalating from
one application in week 1 to two in week 2 and three applications
in weeks 3–8. This was followed by three intramuscular doses of
TA-CIN (1ml of 128mgml
–1) at weeks 10, 14 and 18. The primary
objective was to measure treatment effect on VIN by lesion size
and histology and the secondary objectives were to assess lesion
HPV status, symptoms, immune responses as well as safety,
toxicity and tolerability. Women were reviewed at weeks 0, 10, 14,
18, 20, 26 and 52, the primary end point. Punch biopsies were
taken for histology and HPV typing at weeks 0, 10, 20 and 52.
Heparinised blood (40ml) was obtained for immunological assays
at weeks 0, 10 and 20.
Clinical response
Complete regression of VIN on histopathology of an index
lesion(s) was designated the lesion response. Histological assess-
ment was performed on formalin-fixed punch biopsies. Biopsies
were analysed for HPV typing by reverse line blot assay, which is
able to amplify and detect 37 HPV genotypes (Gravitt et al, 1998).
Safety, tolerability and toxicity were assessed clinically, supple-
mented by FBC and serum biochemistry at weeks 0, 10 and 20. A
full record of adverse events was kept. Patients were advised to
maintain a symptom diary in a visual analogue scale form. This
was reviewed at clinic visits when patient assessment of vulval
pain, itch, swelling, discharge and/or any other symptoms were
graded as none, mild, moderate or severe. Regression of symptoms
from moderate or severe (interfering with lifestyle) to mild or none
(not interfering with lifestyle) categories was considered to be a
symptom response.
Immunofluorescence
Local immune responses were quantified by assessing the TIL
density on 7mm sections of the punch biopsy frozen in liquid
nitrogen and stored at  801C. TILs from five representative fields
of image were counted for each section. T regulatory cells were
identified by double immunofluorescence labelling for FoxP3 and
CD4. This was performed with mouse IgG2a anti-CD4 (Abcam,
Cambridge, UK) at a concentration of 1:100 and mouse IgG1 anti-
FOXP3 (eBioscience, Hatfield, UK) at a concentration of 1:50 and
respectively detected using goat antimouse IgG2a Alexa Fluor 546
3ml per 1000ml and goat antimouse IgG1 Alexa Fluor 488 at 3ml
per 1000ml (Invitrogen, Paisley, UK). CD8 labelling was performed
using rabbit IgG anti-CD8 (Abcam) at a concentration of 1:100
and was detected using goat anti rabbit-IgG Alexa Fluor 488 at 3ml
per 1000ml. Nuclei were stained with DAPI. Five microscopic fields
were imaged in a step-wise manner for each cellular phenotype
investigated in the VIN biopsies. In most cases, this covered almost
the whole specimen, as the sections were small punch biopsies. The
TIL counting was then performed using Image J image analysis
software version 1.36b (http://rsb.info.nih.gov/ij/), using the cell
counting feature of the software. An independent observer
reviewed a range of slides and the counts differed by no more
than 5%. Results were reported as density per unit area of CD4,
CD8 and double-stained FoxP3CD4 cells.
Peripheral immune response
Peripheral immune response to HPV antigens was assessed by
lymphoproliferative assays. Peripheral blood mononuclear cells
(PBMCs) alone or PBMCs with 25mgml
–1 recombinant HPV
antigens – HPV16 E6E7L2 protein TA-CIN (Xenova Research Ltd.,
Cambridge, UK), HPV16 GST E6, HPV16 GST E7 (Smyth et al,
2004), HPV16L2 (full-length HPV16L2 tagged with 6His at
N-terminus) and TA-GW (HPV 6 L2E7; Xenova Research Ltd.) –
and 2mgwell
–1 PHA were performed as previously described
(Winters et al, 2008). Responses were measured by tritiated
thymidine incorporation after a 5-day incubation of patient
PBMCs with the different antigens. Results are presented as
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sstimulation index (SI), defined as the mean number of counts
incorporated by the antigen-stimulated PBMCs divided by the
mean number of counts for PBMCs in medium alone. A pre-
existing proliferative T-cell response was defined as the SI of X2.
A post-vaccination proliferative T-cell response was defined as a
two-fold increase in the SI compared with the pre-vaccination
value.
Neutralising antibodies to HPV16 pseudovirions were tested as
by the SEAP pseudovirus neutralisation-based assay as previously
described (Karanam et al, 2009).
Statistical analysis
Analyses were performed using ‘Stats Direct Statistical Software’
(StatsDirect Ltd, Altrincham, UK). Differences between responder
and non-responder categories (baseline disease duration; HPV16
positivity; smoking; symptom response at week 52 compared with
baseline) were analysed using Fisher’s exact test. The non-
parametric Mann–Whitney U-test was used to test for differences
in proliferative and lesion T-cell density between groups (lesion
responders and non-responders). The non-parametric Wilcoxon’s
signed-ranks test was used to analyse differences in the responses
within groups at different time points. All reported P-values are
two sided and have not been adjusted for multiple comparisons. A
P-value of p0.05 was considered to indicate statistical significance.
RESULTS
A total of 20 women consented to the trial. One woman, who was
found to have early stromal invasion on the first study biopsy, was
withdrawn from the study and excluded from the analysis, which
left 19 women. Patient demographics are presented in Table 1. The
group had a mean age of 46 years with average disease duration of
7 years (range 1–20 years). Thirteen patients had been previously
treated and seven had at least three previous treatments. Only 4
out of 19 (21%) never previously smoked cigarettes.
Tolerability
The majority of women experienced local inflammation, ulcera-
tion, malaise and flu-like symptoms within the initial few weeks of
imiquimod. Side effects were classed as severe in 14 and moderate
in 5 women. To improve tolerance, treatment-free intervals of no
more than a few days were allowed to achieve the total dose, but to
let the side effects subside. Out of 19 women, 16 (84%) completed
the prescribed course of imiquimod treatment. Three women
noted a marked improvement in facial acne with fewer spots and
smoother skin in general while on imiquimod treatment. TA-CIN,
which was administered intramuscularly into the deltoid muscle,
was well tolerated with no side effects or adverse events.
Response rates
Table 2 reports the VIN lesion size, histology, HPV status and any
patient symptoms at baseline (week 0), after imiquimod (week 10),
after vaccination (week 20) and at 52 weeks. Figure 1A stratifies
lesion size reduction at weeks 10, 20 and 52 compared with week 0.
For example, 74, 85 and 79% of women had a X50% reduction in
the size of lesion at weeks 10, 20 and 52, respectively. However,
patient 8 still had a visible VIN-like lesion at week 52 but the
comprehensive histological analysis indicated resolution of VIN
(Table 2). A background of inflammation and pigmentation can
confound the true assessment of any lesion and emphasises the
need for histological definition of VIN. Figure 1B summarizes the
lesion response and HPV status as well as patient symptom
responses with time. Complete regression of VIN on histology was
32, 58 and 63% at weeks, 10, 20 and 52, respectively. At baseline,
15 out of 19 (79%) women had moderate-to-severe symptoms
compared with 11 out of 19 (58%) at week 10; there was significant
reduction at week 20 to 5 out of 19 (26%) and at week 52 to 4 out of
19 (21%), (P¼0.01). At 0, 10, 20 and 52 weeks, 14, 8, 9 and 10 of
the 19 women were HPV16-positive, respectively, and 16 out of 19
were HPV16 positive on at least one occasion. Three women were
consistently HPV16 negative but two showed other HPV-type
Table 1 Patient demographics
Patient no. Age (years) Focality h/o CIN Smoking Prev treatment Disease duration (years)
1 51 M Yes No LASER
Vulvectomy
Imiquimod
4
2 43 M Yes Yes LASER  49
3 45 M Yes Ex Excision 3
4 40 M Yes Yes Excision 10
5 40 M No Yes Excision  72 0
6 65 M No Ex None 4
7 58 M Yes Yes Excision  3
Vulvectomy
15
8 27 M Yes Yes None 1
9 51 M Hyst Ex Diathermy 1
10 55 U Yes Yes Excision 6
11 51 U No Yes LASER  21 6
12 47 U Yes No None 1
13 56 M Yes Yes None 2
14 43 M Hyst No LASER  2
Excision  1
4
15 48 U No No None 1
16 34 M No Yes LASER
Imiquimod
3
17 22 M No Yes None 1
18 66 M Hyst Yes Excision  5
LASER  4
16
19 35 M Yes Yes Excisions  6
LASER  4
9
Abbreviations: CIN¼cervical intraepithelial neoplasia; Ex¼ex-smoker; Hyst¼h/o hysterectomy; Prev¼previous; M¼multifocal; U¼unifocal.
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sinfection at some point. Of the women who showed lesion
responses at week 52, 5 out of 10 also cleared their HPV16
infection compared with only 1 out of 6 non-responders; however,
this did not reach statistical significance. There were no statistical
differences in the lesion responder and non-responder groups with
respect to disease duration (Table 1) at trial entry (P¼0.58) or
HPV16 detection at baseline (P¼0.66). Out of 19 women, 12 were
active smokers during the trial period. Current smoking habit was
not associated with lesion response (P¼0.1).
Extended follow-up of these patients for an average of
15 months beyond the primary end point of week 52 showed
84% of patients with a X50% reduction in lesion size consistent
with continuing control of VIN (Figure 1A). Unfortunately, biopsy
of any index lesion after week 52 was not performed unless
clinically indicated. Overall, one patient developed microinvasive
disease (patient 7), two had new lesions after week 52 (patients
8 and 17) and one had a recurrence 6 months after the trial end
point (patient 14) (Table 2).
Systemic immune response to HPV16
Pre-existing HPV16 antibodies correlated with documented
HPV16 exposure in 12 out of 15 cases. Overall patient pre-existing
neutralising antibody levels did not differ or alter significantly
after imiquimod or vaccination in either the lesion responders who
cleared VIN histologically or the non-responders who failed to
clear VIN (data not shown).
Lymphoproliferation to HPV antigens was used to analyse
patient systemic cellular immunity to HPV before and after the
imiquimod and vaccination steps in the protocol. In all, 16 women
(84%) showed pre-existing lymphoproliferative response to TA-
CIN (SI of X2), of whom 14 were HPV16 positive on vulval biopsy
on at least one occasion. Of these, 11 were lesion responders and
5 non-responders with no significant difference in magnitude of
pre-existing response (P¼0.4). After vaccination, 10 out of 12
lesion responders compared with 3 out of 7 non-responders
showed more than two-fold SI change compared with baseline.
Figure 2 shows box-plots of the median and quartile lymphopro-
liferative responses of all the patients as well as stratification into
lesion responders or non-responders to the different antigens, TA-
CIN vaccine (HPV16 E6E7L2 fusion protein), its component HPV16
antigens L2, E6 and E7 as GST fusion proteins, TA-GW (HPV6
L2E7 fusion protein) as a negative control and PHA as a positive
control for lymphocyte proliferation. Strong PHA responses were
showed by all the women with median SIs of 12, 10.6, 16.9 at week
0, 10 and 20, respectively; however, these responses were not
significantly different after imiquimod or vaccination (P¼0.4 and
P¼0.2 in the group) or when patients were stratified by lesion
Table 2 Clinical responses in VIN patients treated by imiquimod and TA-CIN
Lesion size in mm Histology HPV type Symptoms
Patient no. Wk 0 Wk 10 Wk 20 Wk 52 Wk 0 Wk 10 Wk 20 Wk 52 Wk 0 Wk 10 Wk 20 Wk 52 Wk 0 Wk 10 Wk 20 Wk 52
1d 80 35 30 40 VIN1/2/3 VIN1/2/3 VIN2/3 VIN2/3 Neg Neg 16 16 Mild Moderate Mild Moderate
2d 75 60 70 70 VIN3 VIN1/2/3 VIN2/3 VIN2/3 16 16 16 16 Severe Moderate Moderate Severe
3 90 65 40 30 VIN2/3 VIN2/3 VIN2/3 VIN1/2 42 Neg Neg Neg Moderate Severe Mild Mild
4d 50 40 30 45 VIN2/3 VIN2/3 VIN2/3 VIN2/3 16 16 16 Neg Severe Moderate Mild Mild
9 4100 25 20 10 VIN3 VIN2/3 VIN2/3 VIN2/3 16 16 16 16 Severe Moderate Mild Mild
16f 45 20 30 40 VIN2/3 VIN2/3 VIN2/3 VIN2/3 16 16 16 16 Severe Severe Severe Severe
18 30 20 10 20 VIN2/3 VIN2/3 VIN2/3 VIN2/3 16 16 16 16 Mild Mild Mild Mild
5 60 10 0 0 VIN1/2/3 No VIN No VIN No VIN 16 Neg Neg Neg Mild Moderate None None
6 65 25 5 0 VIN2/3 No VIN No VIN No VIN 16 16 Neg 16,53 Severe Mild None None
7w 100 50 50 0 VIN3 No VIN No VIN No VIN 16,33,84 Neg N/E 33 Severe Mild Mild Mild
8a 60 25 25 25 VIN2/3 VIN2/3 VIN2 No VIN 16 16,33,81 N/E 16 Severe Severe Severe Severe
10d 25 10 0 0 VIN2/3 VIN1/2/3 No VIN No VIN Neg Neg Neg Neg Severe None None Mild
11 25 0 0 0 VIN3 No VIN No VIN No VIN Neg Neg 84 84 Moderate Moderate None None
12 20 0 0 0 VIN3 VIN1/2 No VIN No VIN Neg 33 Neg 16,33 Moderate Moderate None None
13 50 40 20 0 VIN3 VIN1/2 No VIN No VIN 16 16 16 16 None Mild None None
14b 90 15 15 0 VIN2/3 VIN1/2 No VIN No VIN 16 Neg Neg Neg Moderate None Moderate Mild
15 25 3 0 0 VIN3 No VIN No VIN No VIN 16 Neg 16 Neg Severe None None None
17a 40 3 4 0 VIN2 VIN1/2 No VIN No VIN 16 Neg 16 16 Moderate Moderate Moderate Mild
19 4100 0 0 0 VIN2/3 No VIN No VIN No VIN 16 Neg 6 6 Severe Mild Mild None
Abbreviations: HPV¼human papillomavirus; CIN¼cervical intraepithelial neoplasia; Neg¼negative; N/E¼non-evaluable; VIN2/3¼vulval intraepithelial neoplasia grades 2 and
3; wk¼week. Patient 7 developed ESI (w) at week 30; patients 1, 2, 4 and 10 underwent LASER treatment (d) after trial completion; patient 14 developed recurrence (b)6
months after trial completion and underwent LASER and surgery. Patients 8 and 17 developed new lesions (a) after week 52 treated with LASER. Patient 16 repeated course of
imiquimod (f) after trial completion.
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Figure 1 (A) Reduction in lesion size. Reduction in lesion size by 100%,
450% but o100 and o50% at baseline (week 0), after imiquimod (week
10), after vaccination (week 20), primary end point (week 52) and follow-
up (62 weeks after primary end point) in the group (n¼19). (B) Lesion
and symptom responses. Lesion response (complete disappearance of VIN
on histology), symptom response (regression to mild/none symptoms),
absence of HPV16 on biopsy at baseline (week 0), after imiquimod (week
10), after vaccination (week 20) and primary end point (week 52) in the
group (n¼19).
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sresponse (P¼0.7 and P¼0.5 in responders and P¼0.3 and P¼0.3
in non-responders) (Figure 2A). In contrast, a significant increase
in proliferation to TA-CIN was observed in patients after
vaccination compared with pre-treatment (P¼0.01) and this was
associated with lesion responders (P¼0.008) but not the non-
responders (P¼0.7) (Figure 2B). Similar significant patient
proliferative responses to each of the individual HPV16L2, E6
and E7 antigens after vaccination were observed (P¼0.02, P¼0.01
and P¼0.02, respectively), with this increased proliferation
associated with lesion responders (P¼0.01, P¼0.03 and
P¼0.03) and not non-responders (P¼0.5, P¼0.5 and P¼0.2)
(Figures 2C–E). Specificity of the HPV16 responses was supported
by the absence of any significant increase in patient lympho-
proliferation after vaccination to TA-GW (HPV6 L2E7), in the
responder (P¼0.4) or the non-responder (P¼0.9) groups
(Figure 2F). No significant increase in proliferation to any of
the antigens was noted after imiquimod in any of the patient
groups. Post-vaccination proliferative response to TA-CIN and its
components seems to correlate with the clearance of VIN on
histology.
Tumour-infiltrating lymphocytes
To analyse local immune factors in the vulval biopsies before
treatment, and after imiquimod and vaccination, the densities per
unit area of CD4, CD8 and double-stained FoxP3CD4 (T
regulatory) cells were assessed. Imiquimod treatment was expected
to enhance the local immune infiltration. The data are presented in
Figure 3 as median/scatter plots for all the patients as a group or
stratified by lesion response. In the group as a whole, significant
increases in the number of CD4, CD8 and FoxP3CD4 T cells were
evident by week 20 compared with baseline (P¼0.03, P¼0.01 and
P¼0.04, respectively); a significant increase in CD8 density was
apparent after imiquimod (P¼0.04). At week 20, the increased
CD4 and CD8 density was significantly associated only with the
lesion responders (P¼0.03 and P¼0.03) whereas increased
FoxP3CD4 density was associated with the patients who did not
show lesion response (P¼0.05). There were no significant pre-
treatment differences in the density of CD4 or CD8 T cells in lesion
responder and non-responders (P¼0.2 and P¼0.5, respectively)
but intralesional FoxP3CD4 density was significantly higher in
non-responders compared with responders (P¼0.05). By week 20,
a significant reduction in FoxP3CD4 T-cell population density was
apparent in lesion responders, which was significantly different
from non-responder densities (P¼0.01).
DISCUSSION
This study was designed on the premise that imiquimod and
therapeutic HPV vaccination could combine to alter the balance of
local immunity through inducing a local inflammatory environ-
ment and enhancing T-cell responses to HPV E6 and E7 proteins.
Immunotherapies that tip the balance of immune equilibrium in
favour of the host effector response and away from regulatory and
viral evasion strategies of the HPV may be the key to enhancing
the cell-mediated immunity required to eradicate persistent
HPV infection and established disease. This study showed that
imiquimod followed by vaccination achieved histological clearance
of VIN at 52 weeks in almost 60% of a heavily pre-treated cohort of
women with high-grade, long-standing VIN.
With the proviso that the study size was small, the analyses of
lesion-associated T cells showed that higher pre-existing and post-
treatment levels of regulatory T cells are associated with a lack of
lesion response to treatment. As expected in the group as a whole,
imiquimod treatment induced T-cell infiltration, which was most
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Figure 2 Box-feather plots showing median and quartile lymphoproliferation responses. The figures show stimulation indices of proliferation in response
to PHA (A), TA-CIN (B), HPV-16L2 (C), GST-E6 (D), GST-E7 (E) and TA-GW (F) in the whole group (n¼19), lesion responders (R; n¼12) and lesion
non-responders (NR; n¼7) at baseline (week 0), after imiquimod (week 10) and after vaccination (week 20). P-values that are statistically significant for
stimulation indices (SI) at week 20 compared with week 0 are shown. The Wilcoxon’s signed-ranks test was used to determine the significance of within-
group differences before and after treatment. A P-value of p0.05 was considered significant.
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sapparent by week 20. However, the increased CD4 and CD8 T-cell
density was significant only in the lesion responder group, whereas
a significantly higher regulatory T-cell density was only observed
in the non-responder group. These observations are consistent
with immune control and therapeutic effect reflecting the balance
of useful CD4- and CD8-directed effectors against their control by
T regulatory activity. Thus, increasing the CD8 and CD4 T-cell
density may be able to re-establish local immune control that is
lost or suppressed in chronic VIN (Gul et al, 2004). Where the
T regulatory cells dominate the local immunological milieu, they
can continue to suppress the HPV antigen-specific cytotoxic T-cell
response facilitating persistent VIN (Kobayashi et al, 2004; Stanley,
2008). T regulatory depletion before imiquimod or therapeutic
vaccination, particularly in women with higher proportion of
systemic or intralesional T regulatory cells before treatment, might
enhance the stimulation and efficacy of the useful HPV-specific
effector T cells. Indeed, there have been several attempts to
improve the outcome of different vaccination regimes either by
downregulating or blocking T regulatory cells with anti-CD25
antibodies (Chuang et al, 2009) or IL-2 diphtheria toxin conjugates
(Dannull et al, 2005).
The TA-CIN vaccination component of the protocol was aimed
at expanding E6- and E7-specific T effectors with the possibility
that after imiquimod their entry and activity in the VIN lesions
would not be limited by local immunosuppressive factors.
Lymphoproliferation of PBMCs established that all patients were
immunocompetent and that the vaccination was immunogenic and
HPV16 antigen specific. Importantly, these systemic immune
responses to HPV16 antigens were significantly associated with
lesion responders and not the non-responders. There was no
influence on immunity to HPV as a result of the imiquimod
treatment. However, a trend towards higher pre-existing responses
to HPV16 early antigens in the lesion responder group was noted
in this study, which was significantly stimulated by the vaccina-
tion. In contrast, the lesion non-responders showed little pre-
existing response and this was not boosted by the vaccine.
Previous studies have noted a significant correlation between pre-
existing systemic HPV16-specific T cells and regression of HPV16-
positive lesions (Van Poelgeest et al, 2005; Winters et al, 2008).
The immune response to the HPV vaccine used in this study might
have additional effect if delivered with an adjuvant that can boost
both serological and cellular immune responses to its HPV16
antigens (Karanam et al, 2009).
Overall, it seems that the natural history of the VIN in the non-
responders is related to modulation of both local and systemic
immune responses allowing persistence of HPV infection. The
mechanisms underlying this chronic VIN state are not known but
might include genetic predisposition involving immune and other
parameters (Davidson et al, 2003b). In chronic VIN the suboptimal
stimulation of HPV immunity probably also leads to anergy of
HPV-specific T effectors. The precise time course of immune
responses relevant to HPV lesion clearance are completely
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Figure 3 Median/scatter-dot plot of lesion-associated immune cells in the group (G), lesion responders (R) and non-responders (NR). The figure shows
median number (density per unit area) of CD4, CD8 and FoxP3CD4 cells before treatment (week 0), after imiquimod (week 10) and after vaccination
(week 20) in the group (G), lesion responders (R) and non-responders (NR). The P-values for statistically significant difference in the number of cells either
at week 10 or week 20 compared with week 0 are shown. The Wilcoxon’s signed-ranks test was used to determine the significance of within-group
differences before and after treatment. A P-value of p0.05 was considered significant.
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sunknown and there is no a priori reason why it would achieve its
full potential at the arbitrary study end point especially for chronic
lesions, which have been present for many years. Thus, although
some of the histological and symptom response noted at week 52
was evident from week 10 (after imiquimod), the response
enhanced with time. It is reasonable to argue that an immunolo-
gically challenged chronic condition that takes time to establish
will equally take time to regress, explaining the continuing
response noted long after treatment completion. In this study of
a heavily pre-treated cohort of women with long-standing disease,
containment of response for 2 years is noteworthy. Patient 5 (40
years, VIN for 20 years and 7 surgical excisions) and patient 19 (35
years, multifocal VIN for 10 years and 10 surgical treatments)
illustrate particularly effective lesion responses achieved by week
52 in this study, and that have been maintained for a further 2
years thus far. In both these cases, intralesional pre-treatment T
regulatory cell density was low, with no enhancement after
treatment, contrary to increased density of CD4 and CD8 cells. A
pre-existing proliferative response to HPV16 with significant
increase in proliferation response after vaccination was also
showed. It would be beneficial if the likelihood of response to
treatment could be determined using biomarkers either before
treatment or, in the case of combined therapy, after imiquimod to
avoid subjecting likely non-responders to unnecessary treatment.
At face value, pre-treatment assessment of dominant immuno-
logical cell types in the lesion microenvironment and analysing
pre-existing immunity to HPV could provide the basis for selecting
patients most likely to benefit from imiquimod with or without
vaccination regimes.
In considering the imiquimod treatment, tolerability is a
significant issue as the majority of women experience local and
systemic side effects lasting for the duration of imiquimod
treatment, which may affect daily activities. Overall, our regimen
was feasible but, as expected, was associated with considerable
imiquimod-induced discomfort necessitating breaks in treatment.
Women with refractory VIN are, however, highly motivated to
comply with the treatment protocol, and in the event, 85%
persevered with treatment and finished the full course of
imiquimod. In this study, treatment by 8 weeks of imiquimod
followed by vaccination gave a lesion response rate of 63% at week
52. This compares very favourably with imiquimod alone
treatment of 16 weeks assessed as histological regression to VIN1
or better as 64% soon after treatment (Le et al, 2007) or with no
VIN at 2 months after treatment as 81% (Mathiesen et al, 2007) or
69% (van Seters et al, 2008).
A recent study of VIN patients treated by 3 or 4 immunizations
at 3 weekly intervals with a HPV vaccine composed of long HPV16
E6/E7 peptides in adjuvant (Montanide ISA-51, Seppic)
showed 60 and 79% lesion size response rate (X50% reduction)
at 3 and 12 months of follow-up (Kenter et al, 2009). As suggested
by Kenter et al (2009) imiquimod might be more beneficial if
used after therapeutic HPV vaccination, as studies indicate that
imiquimod treatment may depend on IFN-g producing HPV-
specific T cells.
Following another recently published study of imiquimod
followed by PDT (Winters et al, 2008), continued surveillance
for up to 3 years (S Daayana, unpublished results) has shown a
sustained clinical response rate of 65% at follow-up. This
treatment is now being offered to women in our unit for whom
surgical therapy is not suitable. Distinguishing the contribution of
the individual components of such combination regimes and
establishing proof of either additive or synergistic effects will
require further innovative trials. All the recent studies of
immunologically driven treatments of VIN provide momentum
for further multicentre randomised trials with consistency in
measurement of outcomes and definitions of response. Comparing
upfront surgical treatment with imiquimod or other potentially
more potent TLR agonists (Fahey et al, 2009) or therapeutic HPV
vaccination (Karanam et al, 2009; Kenter et al, 2009), or a
combination of TLR agonists with therapeutic HPV vaccination in
a crossover study design will be valuable.
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